Clostridium difficile infection in the inflammatory bowel disease patient

Inflammatory Bowel Diseases

Volumn 19, Issue 1, 2013, Pages 194-204

  Berg, Adam M ^a,c   Kelly, Ciarán P ^b   Farraye, Francis A ^a,c  

^a BOSTON MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic associated diarrhea; Binary toxin; Clostridium difficile; Colonization; Crohn's disease; Fecal transplantation; Fidaxomicin; Inflammatory bowel disease; Metronidazole; Nitazoxanide; Pseudomembranous colitis; Teicoplanin; Toxin A; Toxin B; Ulcerative colitis; Vancomycin

Indexed keywords

ADP RIBOSYLATING BINARY TOXIN; BACITRACIN; CLOSTRIDIUM TOXIN; CLOSTRIDIUM TOXIN A; CLOSTRIDIUM TOXIN B; FIDAXOMICIN; FUSIDIC ACID; METRONIDAZOLE; NITAZOXANIDE; PROBIOTIC AGENT; RIFAMPICIN; RIFAXIMIN; TEICOPLANIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADAPTIVE IMMUNITY; ANEMIA; BACTERIAL VIRULENCE; BACTERIUM CULTURE; CANADA; CLOSTRIDIUM DIFFICILE INFECTION; COLON DILATATION; COLON PERFORATION; CYTOTOXICITY TEST; DIARRHEA; DISEASE SEVERITY; ENTERITIS; ENZYME IMMUNOASSAY; EPIDEMIC; EUROPE; FEVER; HOSPITALIZATION; HUMAN; HUMORAL IMMUNITY; HYPOALBUMINEMIA; ILEUS; IMMUNE RESPONSE; INCIDENCE; INNATE IMMUNITY; INTENSIVE CARE; LENGTH OF STAY; LEUKOCYTOSIS; META ANALYSIS (TOPIC); MORTALITY; MULTICENTER STUDY (TOPIC); MULTIPLE ORGAN FAILURE; NAUSEA; NONHUMAN; NORTH AMERICA; NUCLEIC ACID AMPLIFICATION; PATHOGENESIS; PATHOGENICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; SHIFT TO THE LEFT; SYSTEMATIC REVIEW (TOPIC); TOXIC MEGACOLON; UNITED KINGDOM; UNITED STATES;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 84873727471     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22964     Document Type: Review

References (129)

1. Bossuyt P, Verhaegen J, Van Assche G, et al. Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. J Crohns Colitis. 2009;3:4-7.
2. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5: 345-351.
3. Clayton EM, Rea MC, Shanahan F, et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: anassessment of carriage in an outpatient setting among patients inremission. Am J Gastroenterol. 2009;104:1162-1169.
4. Rodemann JF, Dubberke ER, Reske KA, et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:339-344.
5. Ananthakrishnan AN, Issa M, Binion DG. Clostridium difficile and inflammatory bowel disease. Med Clin North Am. 2010;94:135-153.
6. Kelly CP. A 76-year-old man with recurrent Clostridium difficile-associated diarrhea: review of C. difficile infection. JAMA. 2009;301:954-962.
7. Epple HJ. Therapy-and non-therapy-dependent infectious complications in inflammatory bowel disease. Dig Dis. 2009;27:555-559.
8. McFarland LV. Update on the changing epidemiology of Clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol. 2008; 5:40-48.
9. Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342:390-397.
10. Kuehn BM. Scientists seek strategies to prevent Clostridium difficile infections. JAMA. 2010;306:1849-1850.
11. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome aftertreatment of Clostridium difficile colitis with metronidazole. ClinInfect Dis. 2005;40:1586-1590.
12. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med. 2002;346:334-339.
13. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med. 1994;330:257-262.
14. Freeman J, Bauer MP, Baines SD, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev. 2010;23: 529-549.
15. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis. 2006;12:409-415.
16. QuickStats: Rates of Clostridium difficile infection among hospitalized patients aged $65 years, by age group-National Hospital Discharge Survey, United States, 1996-2009. CDD Morbidity and Mortality Weekly Report (MMWR). 2011;60.
17. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004; 171:466-472.
18. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31: 431-455.
19. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57:205-210.
20. Ananthakrishnan AN, McGinley EL, Saeian K, et al. Temporaltrends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:976-983.
21. Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of theprevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103: 1443-1450.
22. Ricciardi R, Ogilvie JW Jr, Roberts PL, et al. Epidemiology of Clostridium difficile colitis in hospitalized patients with inflammatory bowel diseases. Dis Colon Rectum. 2009;52:40-55.
23. Goodhand JR, Alazawi W, Rampton DS. Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther. 2010;33:428-541.
24. Just I, Gerhard R. Large clostridial cytotoxins. Rev Physiol Biochem Pharmacol. 2004;152:23-47.
25. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev. 2005;18:247-263.
26. Lyras D, O'Connor JR, Howarth PM, et al. Toxin B is essential for virulence of Clostridium difficile. Nature. 2009;458:1176-1179.
27. Kuehne SA, Cartman ST, Heap JT, et al. The role of toxin A and toxin B in Clostridium difficile infection. Nature. 2010;467:711-713.
28. Davies AH, Roberts AK, Shone CC, et al. Super toxins from a superbug: structure and function of Clostridium difficile toxins. Biochem J. 2011; 436:517-526.
29. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079-1084.
30. Sirard S, Valiquette L, Fortier LC. Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulenceassociated phenotypes. J Clin Microbiol. 2011;49:4040-4046.
31. Jobe BA, Grasley A, Deveney KE, et al. Clostridium-difficile colitis-an increasing hospital-acquired illness. Am J Surg. 1995;169:480-483.
32. Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium-difficile colitis. Dis Colon Rectum. 1995;38:350-354.
33. Jodorkovsky D, Young Y, Abreu MT. Clinical outcomes of patientswith ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci. 2010;55:415-420.
34. Kariv R, Navaneethan U, Venkatesh PG, et al. Impact of Clostridiumdifficile infection in patients with ulcerative colitis. J Crohns Colitis. 2011;5:34-40.
35. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134:577-594.
36. Kelly CP, Pothoulakis C, Orellana J, et al. Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. Gastroenterology. 1992; 102:35-40.
37. Warny M, Vaerman JP, Avesani V, et al. Human antibody responseto Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun. 1994;62:384-389.
38. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011; 365:1693-703.
39. Jangi S, Lamont JT. Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. J Pediatr Gastroenterol Nutr. 2011;51:2-7.
40. Kyne L, Farrell RJ, Kelly CP. Clostridium difficile. Gastroenterol Clin North Am. 2001;30:753-777, ix-x.
41. Marciniak C, Chen D, Stein AC, et al. Prevalence of Clostridium difficile colonization at admission to rehabilitation. Arch Phys Med Rehabil. 2006;87:1086-1090.
42. Rivera EV, Woods S. Prevalence of asymptomatic Clostridium difficile colonization in a nursing home population: a cross-sectional study. J Gend Specif Med. 2003;6:27-30.
43. Kelly CP, LaMont JT. Clostridium difficile infection. Annu Rev Med. 1998;49:375-390.
44. Ben-Horin S, Margalit M, Bossuyt P, et al. Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. J Crohns Colitis. 2010; 4:194-198.
45. Powell N, Jung SE, Krishnan B. Clostridium difficile infection andinflammatory bowel disease: a marker for disease extent? Gut. 2008;57: 1183-1184; author reply 4.
46. Kim JH, Muder RR. Clostridium difficile enteritis: a review andpooled analysis of the cases. Anaerobe. 2011;17:52-55.
47. Holubar SD, Cima RR, Sandborn WJ, et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2010;CD001176.
48. Shen B, Remzi FH, Fazio VW. Fulminant Clostridium difficile-associated pouchitis with a fatal outcome. Nat Rev Gastroenterol Hepatol. 2009;6:492-495.
49. Shen BO, Jiang ZD, Fazio VW, et al. Clostridium difficile infection in patients with ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2008;6:782-788.
50. McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohortof hospitalized patients. J Infect Dis. 1990;162:678-684.
51. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170:784-790.
52. Bolton RP, Sherriff RJ, Read AE. Clostridium difficile associated diarrhoea: a role in inflammatory bowel disease? Lancet. 1980;1:383-384.
53. Trnka YM, LaMont JT. Association of Clostridium difficile toxinwith symptomatic relapse of chronic inflammatory bowel disease. Gastroenterology. 1981;80:693-696.
54. Kutty PK, Woods CW, Sena AC, et al. Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA. Emerg Infect Dis. 2010;16:197-204.
55. Hirshon JM, Thompson AD, Limbago B, et al. Clostridium difficile Infection in Outpatients, Maryland and Connecticut, USA, 2002-2007. Emerg Infect Dis. 2011;17:1946-1949.
56. Kelsen JR, Kim J, Latta D, et al. Recurrence rate of clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:50-55.
57. Das R, Feuerstadt P, Brandt LJ. Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with clostridium difficile-associated disease. Am J Gastroenterol. 2010; 105:2040-2049.
58. Schneeweiss S, Korzenik J, Solomon DH, et al. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. 2009;30:253-264.
59. Stevens V, Dumyati G, Brown J, et al. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure. Pharmacoepidemiol Drug Saf. 2010;20:1035-1042.
60. Linsky A, Gupta K, Lawler EV, et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170: 772-778.
61. Turco R, Martinelli M, Miele E, et al. Proton pump inhibitors as arisk factor for paediatric Clostridium difficile infection. Aliment Pharmacol Ther. 2010;31:754-759.
62. Deshpande A, Pant C, Pasupuleti V, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a metaanalysis. Clin Gastroenterol Hepatol. 2012;10:225-233.
63. Lowe DO, Mamdani MM, Kopp A, et al. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a populationbased study. Clin Infect Dis. 2006;43:1272-1276.
64. Pascarella F, Martinelli M, Miele E, et al. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease. J Pediatr. 2009;154: 854-858.
65. Thomson AB, Sauve MD, Kassam N, et al. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol. 2010;16: 2323-2330.
66. Kyne L, Sougioultzis S, McFarland LV, et al. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol. 2002;23:653-659.
67. Kelly CP, Kyne L. The host immune response to Clostridium difficile. J Med Microbiol. 2010;60:1070-1079.
68. Garey KW, Sethi S, Yadav Y, et al. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008;70: 298-304.
69. Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357:189-193.
70. Hu MY, Katchar K, Kyne L, et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology. 2009;136:1206-1214.
71. McFarland LV, Mulligan ME, Kwok RY, et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320:204-210.
72. Walker RC, Ruane PJ, Rosenblatt JE, et al. Comparison of culture, cytotoxicity assays, and enzyme-linked immunosorbent assay for toxin A and toxin B in the diagnosis of Clostridium difficile-related enteric disease. Diagn Microbiol Infect Dis. 1986;5:61-69.
73. Barbut F, Kajzer C, Planas N, et al. Comparison of three enzyme immunoassays, a cytotoxicity assay, and toxigenic culture for diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol. 1993; 31:963-967.
74. Merz CS, Kramer C, Forman M, et al. Comparison of four commercially available rapid enzyme immunoassays with cytotoxin assay for detection of Clostridium difficile toxin(s) from stool specimens. J Clin Microbiol. 1994;32:1142-1147.
75. Kuehne SA, Cartman ST, Minton NP. Both, toxin A and toxin B, are important in Clostridium difficile infection. Gut Microbes. 2011;2: 252-255.
76. Deshpande A, Pasupuleti V, Patel P, et al. Repeat stool testing to diagnose Clostridium difficile infection using enzyme immunoassay does not increase diagnostic yield. Clin Gastroenterol Hepatol. 2011;9:665-669e1.
77. Snell H, Ramos M, Longo S, et al. Performance of the TechLab C.DIFF CHEK-60 enzyme immunoassay (EIA) in combination withthe C. difficile Tox A/B II EIA kit, the Triage C. difficile panel immunoassay, and a cytotoxin assay for diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol. 2004;42:4863-4865.
78. Zheng L, Keller SF, Lyerly DM, et al. Multicenter evaluation of a new screening test that detects Clostridium difficile in fecal specimens. J Clin Microbiol. 2004;42:3837-3840.
79. Kufelnicka AM, Kirn TJ. Effective utilization of evolving methods for the laboratory diagnosis of Clostridium difficile infection. ClinInfect Dis. 2011;52:1451-1457.
80. Zidaric V, Kevorkijan BK, Oresic N, et al. Comparison of two commercial molecular tests for the detection of Clostridium difficile in the routine diagnostic laboratory. J Med Microbiol. 2011;60:1131-1136.
81. Babady NE, Stiles J, Ruggiero P, et al. Evaluation of the Cepheid Xpert Clostridium difficile Epi assay for diagnosis of Clostridium difficile infection and typing of the NAP1 strain at a cancer hospital. J Clin Microbiol. 2010;48:4519-5624.
82. Kok J, Wang Q, Thomas LC, et al. Presumptive identification of Clostridium difficile strain 027/NAP1/BI on Cepheid Xpert: interpret with caution. J Clin Microbiol. 2011;49:3719-3721.
83. Svensson AM, Lasala PR. Pathology consultation on detection of Clostridium difficile. Am J Clin Pathol. 2011;137:10-15.
84. Wullt M, Odenholt I, Walder M. Activity of three disinfectants and acidified nitrite against Clostridium difficile spores. Infect Control Hosp Epidemiol. 2003;24:765-768.
85. Ben-Horin S, Margalit M, Bossuyt P, et al. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection. Clin Gastroenterol Hepatol. 2009;7:981-987.
86. Yanai H, Nguyen GC, Yun L, et al. Practice of gastroenterologists in treating flaring inflammatory bowel disease patients with clostridium difficile: antibiotics alone or combined antibiotics/immunomodulators? Inflamm Bowel Dis. 2011;17:1540-1546.
87. Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease: more questions than answers? Inflamm Bowel Dis. 2010;16:1445-1446.
88. Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45: 302-307.
89. Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev. 2007;CD004610.
90. Fekety R, Silva J, Kauffman C, et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med. 1989;86:15-19.
91. Friedenberg F, Fernandez A, Kaul V, et al. Intravenous metronidazole for the treatment of Clostridium difficile colitis. Dis Colon Rectum. 2001; 44:1176-1180.
92. Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis. 2002;35:690-696.
93. Apisarnthanarak A, Khoury H, Reinus WR, et al. Severe Clostridium difficile colitis: the role of intracolonic vancomycin? Am J Med. 2002; 112:328-329.
94. Maroo S, Lamont JT. Recurrent clostridium difficile. Gastroenterology. 2006;130:1311-1316.
95. Wilcox MH, Fawley WN, Settle CD, et al. Recurrence of symptoms in Clostridium difficile infection-relapse or reinfection? J HospInfect. 1998;38:93-100.
96. Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol. 1985;80:867-868.
97. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2011;31: 431-455.
98. Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis. 2006;43:421-427.
99. Musher DM, Logan N, Bressler AM, et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis. 2009;48:e41-46.
100. Lagrotteria D, Holmes S, Smieja M, et al. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis. 2006;43:547-552.
101. Garey KW, Jiang ZD, Bellard A, et al. Rifaximin in treatment ofrecurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol. 2009;43:91-93.
102. Garey KW, Ghantoji SS, Shah DN, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother. 2011;66:2850-2855.
103. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomy-cinfor Clostridium difficile infection. N Engl J Med. 2011;364: 422-431.
104. Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis. 2011;53:440-447.
105. Neff G, Zacharias V, Kaiser TE, et al. Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: A case series. Liver Transpl. 2011;16:960-963.
106. O'Connor JR, Galang MA, Sambol SP, et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother. 2008;52:2813-2817.
107. Nelson RL, Kelsey P, Leeman H, et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev. 2011;9:CD004610.
108. Wenisch C, Parschalk B, Hasenhundl M, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis. 1996;22:813-818.
109. Drekonja DM, Butler M, Macdonald R, et al. Comparative effectiveness of Clostridium difficile treatments: a systematic review. Ann Intern Med. 2011;155:839-847.
110. Larson KC, Belliveau PP, Spooner LM. Tigecycline for the treatment of severe Clostridium difficile infection. Ann Pharmacother. 2011;45: 1005-1010.
111. Kopterides P, Papageorgiou C, Antoniadou A, et al. Failure of tigecycline to treat severe Clostridium difficile infection. Anaesth Intensive Care. 2011;38:755-758.
112. Na X, Kelly C. Probiotics in Clostridium difficile Infection. J Clin Gastroenterol. 2011;45(Suppl):S154-158.
113. Dendukuri N, Costa V, McGregor M, et al. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ. 2005;173:167-170.
114. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebocontrolled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271:1913-1918.
115. Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev. 2008;CD004611.
116. Bengmark S. Colonic food: pre-and probiotics. Am J Gastroenterol. 2000;95:S5-7.
117. Hedin C, Whelan K, Lindsay JO. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc. 2007;66:307-315.
118. DuPont AW, DuPont HL. The intestinal microbiota and chronic disorders of the gut. Nat Rev Gastroenterol Hepatol. 2011;8:523-531.
119. Garborg K, Waagsbo B, Stallemo A, et al. Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea. Scand J Infect Dis. 2011;42:857-861.
120. Rohlke F, Surawicz CM, Stollman N. Fecal flora reconstitution forrecurrent Clostridium difficile infection: results and methodology. J Clin Gastroenterol. 2010;44:567-570.
121. Silverman MS, Davis I, Pillai DR. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol. 2011;8:471-473.
122. Yoon SS, Brandt LJ. Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. J Clin Gastroenterol. 2010;44:562-566.
123. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9:1044-1049.
124. Kelly CR, de Leon L, Jasutkar N. Fecal microbiota transplantation for relapsing Clostridium difficile Infection in 26 patients: methodology and results. J Clin Gastroenterol. 2012;46:145-149.
125. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011;53:994-1002.
126. Abougergi MS, Broor A, Cui W, et al. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. J Hosp Med. 2011;5:E1-9.
127. Leav BA, Blair B, Leney M, et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine. 2011;28:965-969.
128. Pepin J, Routhier S, Gagnon S, et al. Management and outcomes ofa first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis. 2006;42:758-764.
129. Wilcox MH, Smyth ET. Incidence and impact of Clostridium difficile infection in the UK, 1993-1996. J Hosp Infect. 1998;39:181-187.